Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pulmo BioTech has reported details of the methodology and purpose of its Phase I human trials with its PulmoBind molecular imaging technology for the diagnosis of pulmonary embolism and pulmonary hypertension.
Subscribe to our email newsletter
The study will be a single center, Phase I safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung disease. It will be carried out by the Pulmo BioTech subsidiary, PulmoScience Inc.
The study outcomes will be safety – to determine pharmacokinetics and biodistribution of PulmoBind in humans and to perform dosimetric evaluation, and efficacy – to evaluate the ability of PulmoBind to allow lung perfusion imaging in humans. Pulmo BioTech expects this work to be completed by late summer 2008.